Loading…

Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro

Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2005-08, Vol.56 (2), p.360-364
Main Authors: Ittner, K. P., Roth, G., Gruber, M., Pawlik, M., Taeger, K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963
cites cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963
container_end_page 364
container_issue 2
container_start_page 360
container_title Journal of antimicrobial chemotherapy
container_volume 56
creator Ittner, K. P.
Roth, G.
Gruber, M.
Pawlik, M.
Taeger, K.
description Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.
doi_str_mv 10.1093/jac/dki205
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68431152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>886212371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</originalsourceid><addsrcrecordid>eNpd0N9LHDEQwPFQKvW0fekfUBahRYWtmWSTvTyW88dZrvRFRXwJc9mk5tzd2GRXrv-9kTsU-jQP82EYvoR8BvodqOInKzQnzYNnVLwjE6gkLRlV8J5MKKeirCvBd8leSitKqRRy-oHsglBTTpmYkMWstRixN7YIrujC2rs2rNH4vmjG6Ps_hQn94PsxjKm4R9sF59sh4uBDXxzObm7m50dFxk9-iOEj2XHYJvtpO_fJ9fnZ1WxeLn5fXM5-LEpTgRxKgdJIZiksoXZLaSurGgZMMGeAOUDDJaraKpQMlo41FVfo2LRxTAgDSvJ98m1z9zGGv6NNg-58MrZtsbf5Ty2nFQcQLMOD_-AqjLHPv2kGtZRK0Sqj4w0yMaQUrdOP0XcY_2mg-iWwzoH1JnDGX7YXx2Vnmze6LZrB1y3AZLB1L219enMyu1rR7MqN82mw69c9xgcta14LPb-906cXpz_ru1-3mvFn5zCSfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217669904</pqid></control><display><type>article</type><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><source>Oxford Journals Online</source><creator>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</creator><creatorcontrib>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</creatorcontrib><description>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dki205</identifier><identifier>PMID: 15983025</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - pharmacokinetics ; antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Area Under Curve ; artificial membranes ; Aza Compounds - blood ; Aza Compounds - pharmacokinetics ; Biological and medical sciences ; Culture Media ; dosage recommendations ; Erythrocytes - metabolism ; Fluoroquinolones ; Hemofiltration ; Humans ; In Vitro Techniques ; Medical sciences ; Metabolic Clearance Rate ; Models, Biological ; Pharmacology. Drug treatments ; Quinolines - blood ; Quinolines - pharmacokinetics ; renal failure ; renal replacement therapy</subject><ispartof>Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.360-364</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Aug 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</citedby><cites>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16983790$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15983025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Roth, G.</creatorcontrib><creatorcontrib>Gruber, M.</creatorcontrib><creatorcontrib>Pawlik, M.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</description><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Area Under Curve</subject><subject>artificial membranes</subject><subject>Aza Compounds - blood</subject><subject>Aza Compounds - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Culture Media</subject><subject>dosage recommendations</subject><subject>Erythrocytes - metabolism</subject><subject>Fluoroquinolones</subject><subject>Hemofiltration</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines - blood</subject><subject>Quinolines - pharmacokinetics</subject><subject>renal failure</subject><subject>renal replacement therapy</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpd0N9LHDEQwPFQKvW0fekfUBahRYWtmWSTvTyW88dZrvRFRXwJc9mk5tzd2GRXrv-9kTsU-jQP82EYvoR8BvodqOInKzQnzYNnVLwjE6gkLRlV8J5MKKeirCvBd8leSitKqRRy-oHsglBTTpmYkMWstRixN7YIrujC2rs2rNH4vmjG6Ps_hQn94PsxjKm4R9sF59sh4uBDXxzObm7m50dFxk9-iOEj2XHYJvtpO_fJ9fnZ1WxeLn5fXM5-LEpTgRxKgdJIZiksoXZLaSurGgZMMGeAOUDDJaraKpQMlo41FVfo2LRxTAgDSvJ98m1z9zGGv6NNg-58MrZtsbf5Ty2nFQcQLMOD_-AqjLHPv2kGtZRK0Sqj4w0yMaQUrdOP0XcY_2mg-iWwzoH1JnDGX7YXx2Vnmze6LZrB1y3AZLB1L219enMyu1rR7MqN82mw69c9xgcta14LPb-906cXpz_ru1-3mvFn5zCSfg</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Ittner, K. P.</creator><creator>Roth, G.</creator><creator>Gruber, M.</creator><creator>Pawlik, M.</creator><creator>Taeger, K.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><author>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Area Under Curve</topic><topic>artificial membranes</topic><topic>Aza Compounds - blood</topic><topic>Aza Compounds - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Culture Media</topic><topic>dosage recommendations</topic><topic>Erythrocytes - metabolism</topic><topic>Fluoroquinolones</topic><topic>Hemofiltration</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines - blood</topic><topic>Quinolines - pharmacokinetics</topic><topic>renal failure</topic><topic>renal replacement therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Roth, G.</creatorcontrib><creatorcontrib>Gruber, M.</creatorcontrib><creatorcontrib>Pawlik, M.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ittner, K. P.</au><au>Roth, G.</au><au>Gruber, M.</au><au>Pawlik, M.</au><au>Taeger, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>56</volume><issue>2</issue><spage>360</spage><epage>364</epage><pages>360-364</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15983025</pmid><doi>10.1093/jac/dki205</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.360-364
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_68431152
source Oxford Journals Online
subjects Anti-Bacterial Agents - blood
Anti-Bacterial Agents - pharmacokinetics
antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Area Under Curve
artificial membranes
Aza Compounds - blood
Aza Compounds - pharmacokinetics
Biological and medical sciences
Culture Media
dosage recommendations
Erythrocytes - metabolism
Fluoroquinolones
Hemofiltration
Humans
In Vitro Techniques
Medical sciences
Metabolic Clearance Rate
Models, Biological
Pharmacology. Drug treatments
Quinolines - blood
Quinolines - pharmacokinetics
renal failure
renal replacement therapy
title Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A42%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clearance%20of%20moxifloxacin%20during%20continuous%20haemofiltration%20(CVVHF)%20in%20vitro&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Ittner,%20K.%20P.&rft.date=2005-08-01&rft.volume=56&rft.issue=2&rft.spage=360&rft.epage=364&rft.pages=360-364&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dki205&rft_dat=%3Cproquest_cross%3E886212371%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217669904&rft_id=info:pmid/15983025&rfr_iscdi=true